# US 12,215,103 B2 · Fused imidazole derivative, preparation method therefor, and medical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,103 B2
- Document ID: US12215103B2
- Status: Granted
- Kind: B2
- Application number: 18/612,631
- Filed: 2024-03-21
- Published: 2024-07-25
- Granted: 2025-02-04
- Earliest claimed: 2020-09-01
- Assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Applicants: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Inventors: Fanglong Yang; Ling Zhang; Liangliang Zheng; Feng He; Weikang Tao
- Web page: https://patentgrep.com/patent/US12215103B2

## CPC

- C07D 417/14: containing three or more hetero rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07D 405/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

## Claims

### Claim 1

A compound, wherein the compound is selected from the group consisting of:
or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound is:
or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound is:
or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition, comprising the compound of claim 1, or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 5 (depends on 3)

A pharmaceutical composition, comprising the compound of claim 3, or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 6

A compound having the structure of:
or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

A pharmaceutical composition, comprising the compound of claim 6, or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 8 (depends on 2)

A pharmaceutical composition, comprising the compound of claim 2, or a tautomer, racemate, enantiomer or diastereomer thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.